Close menu




January 17th, 2020 | 13:37 CET

Evotec, Memphasys, MorphoSys - Growth Industry Health

  • Health
Photo credits: pixabay.com

He who is healthy has many desires, he who is ill only one. Companies around the globe deal with diseases and special features of nature in order to treat or cure them. In addition to the widespread disease of cancer, there are also topics that are less talked about, but are also a big market. Developments can be of great importance for investors, physicians and the people affected. It can therefore be worthwhile to deal with the variety of topics.

time to read: 1 minutes | Author: Mario Hose
ISIN: AU000000MEM5 , DE0005664809 , DE0006632003

Table of contents:


    Expert for drug discovery

    Evotec claims to be one of the leading suppliers in the field of active ingredient research, drawing on the know-how accumulated over more than two decades. The company has its headquarters in Hamburg and employs more than 2,900 people worldwide. With a share price of EUR 24.65, Evotec's market capitalization is more than EUR 3.6 billion, making it one of the larger companies in the industry.

    Innovations in fertility

    Memphasys from Australia is still in the early stages of its corporate development and is working on the topic of artificial insemination to offer couples who wish to have children an improved chance of success for a successful pregnancy. The company's product is called FELIX and is currently in the test phase. A major market launch is scheduled for the second half of 2020. The value of the company on the stock exchange currently amounts to EUR 26 million and a successful operative development should have a corresponding impact.

    Experience with antibody technologies

    With a share price of EUR 118.70, MorphoSys has a market capitalization of EUR 3.8 billion. According to MorphoSys, it has made a name for itself in the pharmaceutical industry with its antibody technologies. The company develops both its own active ingredients and those of its partners. In drug discovery and development, the Company relies primarily on its innovative technologies. Together with its partners, MorphoSys has built a drug pipeline with more than 100 fully human antibody candidates.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Mario Hose

    Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

    About the author



    Related comments:

    Commented by Nico Popp on November 25th, 2021 | 11:46 CET

    BB Biotech, Sativa Wellness, Carnival: Anti-aging as a megatrend

    • Health

    Anti-aging medicine is one of the most exciting research topics of our time. Already in 2018, Citigroup named the field as one of the ten rising topics of the future. While the pandemic has obscured many long-term ventures in the media, the work continues. People have long been optimizing and working to feel at least a little younger. We present three stocks related to biotechnology, anti-aging and wellness.

    Read

    Commented by Stefan Feulner on February 9th, 2021 | 08:00 CET

    CureVac, Cardiol Therapeutics, Bayer - roaring profits!

    • Health

    The race for the best and most effective vaccine is in full swing. After BioNTech and its partner Pfizer, Moderna and AstraZeneca were approved in Europe, but there are always obstacles. Over the weekend, for example, South Africa announced that it is forgoing the AstraZeneca vaccine for the time being. The background to this is its supposedly lower efficacy with the B.1.351 virus mutation. Somewhat unnoticed, another vaccine manufacturer is moving into pole position through innovative collaborations.

    Read

    Commented by Nico Popp on February 8th, 2021 | 07:30 CET

    Fresenius, Fresenius Medical Care, Q&M Dental: Healthy returns await here

    • Health

    Healthcare stocks have been in demand not just since the pandemic, but the pandemic is a sure game-changer for the industry in the long term. Demand for consumables and tests will continue to rise because this much seems certain: the Coronavirus will remain with us and possibly return year after year like a wave of influenza. Companies in the industry can profit from this. We present three stocks.

    Read